Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial

Rheumatology

Volumn 40, Issue 6, 2001, Pages 615-622

  Furst, D E ^a,b   Clements, P J ^c   Wong, W K ^d   Mayes, M D ^e   Wigley, F ^f   White, B ^g   Weisman, M ^h   Barr, W ⁱ   Moreland, L ^j   Martin, R ^k   Medsger Jr , T A ^l   Steen, V ^m   Collier, D ⁿ   Weinstein, A ^o   Lally, E ^p   Varga, J ^q   Weiner, S R ^c   Andrews, B ^r   Abeles, M ^s   Peter, J B ^c   Seibold, J R ^t   more..

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HUTZEL HOSPITAL   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h UCSD MEDICAL CENTER   (United States)

ⁱ LOYOLA UNIVERSITY   (United States)

^j University of Alabama at Birmingham   (United States)

^k MICHIGAN STATE UNIVERSITY   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^m GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF COLORADO   (United States)

^o GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^p BROWN UNIVERSITY   (United States)

^q UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^t RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

more..

Author keywords

ACR guidelines for systemic sclerosis trials; Organ involvement; Scleroderma; Systemic sclerosis

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 13; CHLORAMBUCIL; COLCHICINE; CYCLOFENIL; DIMETHYL SULFOXIDE; DIPYRIDAMOLE; FLUOROURACIL; ILOPROST; KETANSERIN; KETOTIFEN; METHOTREXATE; METHYLDOPA; PENICILLAMINE; PLACEBO; PROPRANOLOL; RELAXIN; SPIRONOLACTONE; STANOZOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; HEART; HUMAN; HYPERTENSION; HYPOTHESIS; JOINT; LUNG; LUNG FUNCTION; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MUSCLE; PATIENT; PHOTOCHEMOTHERAPY; POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOLOGY; SCORING SYSTEM; SKIN; SYSTEMIC SCLEROSIS;

EID: 0034935514     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/40.6.615     Document Type: Article

References (46)

1. Treatment of systemic sclerosis by disease-modifying agents
2. Why everything (or nothing) seems to work in the treatment of scleroderma
3. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology committee on design and outcomes in clinical trials in systemic sclerosis
4. High dose vs. low dose penicillamine in early diffuse systemic sclerosis trial: Analysis of a two-year, double-blind, randomized controlled clinical treatment trial
5. Spirometric standard for healthy non-smoking adults
6. Respiratory function tests. Normal values at median altitudes and the prediction of normal results
7. Standardized single breath normal values for carbon monoxide and diffusing capacity
8. A controlled trial of anti-hypertensive therapy in systemic sclerosis (scleroderma)
9. Preliminary report on a controlled trial of apheresis in the treatment of scleroderma
10. Immunosuppression with chlorambucil, versus placebo, for scleroderma: Results of a three-year, parallel, randomized, double-blind study
11. Colchicine
12. Tralamiento de la sclerosis systemica progresiva con colchicine. Estudio preliminar
13. Colchicine vs placebo in the treatment of progressive systemic sclerosis (scleroderma)
14. Cyclofenil vs placebo in progressive systemic sclerosis
15. Cyclofenil treatment of scleroderma-controlled study
16. Double-blind multi-center, controlled trial comparing topical dimethyl-sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis
17. Trial of platelet-inhibiting drugs in scleroderma. Double-blind study with dipyridamole and aspirin
18. Treatment of progressive systemic sclerosis using factor XIII
19. Five-fluorouracil in the treatment of scleroderma: A randomized, double-blind, placebo-controlled international collaborative study
20. Intravenous Iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study
21. Ketanserin in the treatment of systemic sclerosis: A double-blind controlled trial
22. A double-blind, randomized, controlled trial of ketotifen vs. placebo in early diffuse scleroderma
23. Measurement of clinical change in progressive systemic sclerosis (PSS): A one year double-blind placebo-controlled trial of n-acetylcysteine
24. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multi-center trial
25. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma
26. Controlled trial of recombinant human relaxin in diffuse scleroderma
27. Sprironolactone treatment in scleroderma- a double-blind therapy study
28. A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis
29. Lack of clinical benefit after treatment of systemic sclerosis with total lymphoid irradiation
30. Methotrexate in systemic sclerosis: Preliminary 24 week results of a placebo-controlled double-blind trial
31. Organ involvement: Cardiac
32. The relationship of arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS)
33. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma
34. The relationship of HBP and renal failure in scleroderma (progressive systemic sclerosis) to structural abnormalities of the renal cortical circulation
35. The kidney in scleroderma
36. Organ involvement: Musculoskeletal in systemic sclerosis
37. Muscle disease in systemic sclerosis
38. Pulmonary function in scleroderma
39. Pulmonary manifestations of progressive systemic sclerosis
40. Organ involvement: Pulmonary
41. Pulmonary involvement in systemic sclerosis
42. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis
43. Prognostic importance of cardiac arrhythmias in systemic sclerosis
44. Progressive systemic sclerosis: Pulmonary involvement
45. Organ involvement: Renal
46. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma)